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Cachexia has long been recognized as a direct cause of reduced
quality of life complicating both the early and late stages of
cancer, particularly in patients with tumours originating in the
pancreas, oesophagus, stomach or lung. Weight loss in cancer
can result from reduced food intake or abnormal metabolism
or, most commonly, a variable combination of the two. These
changes are induced by changes in the neuro-endocrine stress
response and activation of pro-inflammatory cytokine networks.
Loss of adipose tissue (reflecting a negative energy balance) and
wasting of skeletal muscle (reflecting a negative nitrogen balance)
may or may not develop in synchrony. Hepatic protein synthesis
is activated with development of an acute phase protein
response. Central nervous system (CNS) changes include anor-
exia and fatigue. Taken together, these changes are thought to
contribute to the reduced quality and quantity of life associated
with cachexia.
Patients with pancreatic cancer have the highest prevalence and
often develop the most severe degrees of cachexia.1 Traditional
understanding of cachexia has focused on loss of body weight.
However, a number of specific methods currently available to
discriminate detailed body composition have recently indicated
that skeletal muscle and adipose tissue may behave independently
during weight loss. Skeletal muscle wasting is a phenomenon
which, without the aid of body composition analysis, may be
obscured within the bulk of body fat and it has only recently been
recognized that sarcopenia (severe muscle loss to an absolute level
>2 standard deviations below that typical of healthy adults) is
a clinically important phenomenon, even in overweight or obese
patients. The ageing process is often paralleled by decreases
in muscle and increases in fat mass, which may culminate in
sarcopenic obesity. Current literature on human body composition
is becoming highly differentiated and, although this is most
developed in studies of non-malignant conditions such as old age,
diabetes and obesity, current research on cancer cachexia is
increasingly employing such techniques to reveal the true scale of
sarcopenia in both obese and non-obese patients.
The present study by Aslani and co-workers2 examines the rela-
tionship between tumour stage and altered body composition in
patients with resectable pancreatic cancer. The methods employed
include total body potassium counting, assessment of total body
water and estimation of fat mass by anthropometry (skin-fold
thickness). These methods allow for the separation of compart-
ments (fat, protein, water), but not specific subsets within them
(i.e. muscle vs. organs) and are dependent on the availability
of the highly specialized equipment necessary for potassium
measurement. Other recent works on pancreatic cancer cachexia3,4
have made opportunistic use of the computed tomography
(CT) images found in the usual patient record, which allow the
separation of specific muscles and organs, as well as visceral,
subcutaneous and intermuscular adipose tissues. Both CT and
magnetic resonance imaging (MRI)-based approaches have
been validated extensively in non-malignant and, more recently,
malignant disease.5,6
In the study by Aslani et al.,2 patients with more advanced
disease (involved surgical margins) are shown to have more sig-
nificant alterations in body composition, notably decreased body
protein mass and fat mass. The sample size was small and patients
were examined whilst their disease was still resectable. It remains
to be seen whether these early changes predict the later degree
and impact of cachexia on outcome. Interestingly, the presence of
muscle wasting in obese patients with advanced pancreatic cancer
is associated with shortened survival.3
One of the key domains of quality of life that is affected by
cachexia is thought to be physical function.7 New technology
(physical activity monitors) provide a robust, objective measure of
this variable and such monitoring has been suggested as a novel
and important endpoint for cachexia intervention trials.8 Physical
activity level is grossly decreased in advanced cancer patients
with weight loss and may be influenced beneficially by specialized
nutritional support.9 There is, however, little clear information on
the relative importance of altered energy supply, reduced muscle
mass, systemic inflammation or CNS/psychological alterations
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(e.g. fatigue) on physical activity level. Such issues might be
resolved by the development of effective therapy for cachexia and
concomitant use of activity monitoring in proof-of-concept trials.
Recent advances in molecular and cell biology have provided a
range of novel drug targets relevant to the treatment of cachexia.
Interventions may be either upstream (e.g. by antagonizing
key mediators of systemic inflammation) or downstream (e.g. by
blocking catabolic pathways or stimulating anabolic pathways in
skeletal muscle). Upstream targets have the advantage of affecting
multiple aspects of cachexia. For example, interleukin-6 is known
to be the main mediator of the hepatic acute phase response in
humans, but it may also play a role in anorexia, fatigue, anaemia,
oedema and muscle loss. By contrast, myostatin acts as a physi-
ological brake to the continued growth of skeletal muscle and is
therefore a potential downstream target. The blockade of myosta-
tin offers a specific method to induce muscle hypertrophy inde-
pendent of the provision of anabolic signals (e.g. insulin-like
growth factor, IGF-1) which, at least theoretically, might stimu-
late cancer growth. Alternative targets include the melanocortin
pathway in the CNS control of appetite. A powerful stimulus to
increase food intake would potentially improve the mass and
function of many organs and physiological functions. Therapies
based on these pathways are currently in Phase I and Phase II
clinical trials in cancer patients, and the demonstration of their
potential efficacy to stem losses of weight and muscle, alter physi-
cal function and improve quality of life will be available in the
foreseeable future.
Clearly, the best way to treat cachexia is to remove the tumour,
as was investigated by Aslani et al.2 However, for the majority of
patients with pancreatic cancer, resection is not possible and pal-
liation with systemic chemotherapy is the main method of pro-
longing, albeit limited, survival. The balance between potential
improved survival and maintenance of quality of life during che-
motherapy is a key feature of management at this stage. Cachexia
is associated with lower tolerance for chemotherapy, which limits
the total dose that can be delivered, the number of symptomatic
responses and any survival advantage that might be accrued.10–12
Moreover, for the majority who do not respond, cachexia may be
exacerbated by systemic chemotherapy, thus increasing the net
symptom burden experienced by patients.
It is now widely recognized that cachexia is best managed
with a multimodal approach.13 Although specialized nutritional
supplements are associated with weight stabilization, the effects
are limited, which has reduced the enthusiasm of oncologists to
actively pursue such anti-cachexia treatment strategies. It is now
possible to make routine accurate measurements of key outcomes
in cancer cachexia (namely, muscle mass and physical activity).
The arrival of new potent strategies that may effectively reverse
such aspects of cachexia and support patients through palliative
management (including chemotherapy) may herald a new era in
which cachexia and its treatment are seen as essential components
of mainline oncology.
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